Cannabis and Cannabinoid Research, Год журнала: 2024, Номер unknown
Опубликована: Авг. 26, 2024
The chronic effects of cannabidiol (CBD) supplementation on factors that could impact the quality life (anxiety, sleeping quality, memory, etc.) are poorly explored. Hence, aim this study was to establish whether CBD will improve self-reported outcomes related life.
Язык: Английский
Nature Mental Health, Год журнала: 2024, Номер 2(7), С. 865 - 876
Опубликована: Июнь 3, 2024
Abstract Cannabis, one of the most widely used psychoactive substances worldwide, can give rise to acute cannabis-associated psychotic symptoms (CAPS). While distinct study designs have been examine CAPS, an overarching synthesis existing findings has not yet carried forward. To that end, we quantitatively pooled evidence on rates and predictors CAPS ( k = 162 studies, n 210,283 cannabis-exposed individuals) as studied in (1) observational research, (2) experimental tetrahydrocannabinol (THC) (3) medicinal cannabis research. We found varied substantially across designs, given high reported by research (19% 21%, respectively) but studies (2%). was predicted THC administration (for example, single dose, Cohen’s d 0.7), mental health liabilities bipolar disorder, 0.8), dopamine activity 0.4), younger age −0.2), female gender −0.09). Neither candidate genes COMT , AKT1 ) nor other demographic variables education) meta-analytical models. The results reinforce need more closely monitor adverse cannabis-related outcomes vulnerable individuals these may benefit from harm-reduction efforts.
Язык: Английский
Процитировано
3
International Journal of Mental Health and Addiction, Год журнала: 2025, Номер unknown
Опубликована: Апрель 24, 2025
Язык: Английский
Процитировано
0
Molecular Psychiatry, Год журнала: 2025, Номер unknown
Опубликована: Май 19, 2025
Abstract As high-potency cannabis (with high Δ 9 -Tetrahydrocannabinol content) becomes easily accessible and widespread, it is of extreme importance for public health that a scientific platform used to implement practical guidelines, particularly at-risk populations. Many reviews have been written in the past decade summarizing impact developing brain. One critical concept frequently mentioned but not discussed detail whether there are sensitive neurodevelopmental events driving age-specific sensitivity cannabis, those mediated by cannabinoid type 1 receptor signaling. By integrating available data from humans animal models, goal present expert review article provide mechanistic overview on how exposure during periods neural circuit plasticity development can result lasting consequences. Here we frontal cortex as proxy align trajectory brain system between rodents. Both strengths limitations studies effects cannabinoids were using developmental framework which adaptations considered. Such an approach needed key variables through lifespan, turn will valuable insights applicable human defining underpinning mechanisms changes childhood adolescence, thereafter young adulthood.
Язык: Английский
Процитировано
0
Psychopharmacology, Год журнала: 2024, Номер 241(6), С. 1125 - 1134
Опубликована: Фев. 28, 2024
Abstract Rationale Attentional bias to drug-related stimuli is hypothesised contribute towards addiction. However, the acute effects of Δ9-tetrahydrocannabinol (THC) on attentional cannabis cues, differential response in adults and adolescents, moderating effect cannabidiol (CBD) are unknown. Objectives Our study investigated (1) vaporised cannabis-related images adolescents (2) influences age CBD. Methods We conducted a randomised, double-blind, placebo-controlled, cross-over where three weight-adjusted preparations: ‘THC’ (8 mg THC for 75-kg person), ‘THC + CBD’ 24 CBD person) PLA (matched placebo). Cannabis was administered 3 separate days 48 participants, who used 0.5–3 days/week: (12 females, aged 16–17) 26–29). Participants completed visual probe task with cues. primary outcome stimuli, measured using reaction time vs. neutral probe, 200-ms trials. Results In contrast hypotheses, attention directed away from cues placebo, there main drug ( F (2,92) = 3.865, p 0.024, η 2 0.077), indicating administration eliminated this bias. There no significant impact nor an age-by-drug interaction. Conclusions Acute intoxication evidence compared that moderate dose altered Trial registration This listed US National Library Medicine registered ClinicalTrials.gov, URL: Do Adolescents Adults Differ Their Response Cannabis?—Full Text View—ClinicalTrials.gov , number: NCT04851392.
Язык: Английский
Процитировано
2
International Journal of Drug Policy, Год журнала: 2024, Номер 128, С. 104457 - 104457
Опубликована: Май 20, 2024
The legalization of cannabis in Canada has accelerated the need for a standardized approach to measuring and communicating amount delta-9-tetrahydrocannabinol (THC) products. This article offers an overview considerations associated with establishing implementing standard THC unit Canadian context. begins by discussing applications unit, emphasizing its potential use product labelling, consumer education, reporting surveillance. then examines key identifying what should be set at, specifically within context country regulated commercial market. is followed discussion additional related adoption including across various formats modes administration. A significant focus this on prioritizing public health safety informed decision-making among adult consumers as legal market evolves. Collaboration stakeholders, such government agencies, industry, professionals, highlighted crucial successful transition Canada's unit.
Язык: Английский
Процитировано
2
Supportive Care in Cancer, Год журнала: 2024, Номер 32(4)
Опубликована: Март 5, 2024
Abstract Purpose Cannabis use may introduce risks and/or benefits among people living with cancer, depending on product type, composition, and nature of its use. Patient knowledge tetrahydrocannabinol (THC) or cannabidiol (CBD) concentration could provide information for providers about cannabis during after treatment that aide in risk benefit assessments. This study aimed to examine THC CBD patients cancer who consume cannabis, factors associated cannabinoid concentrations. Methods People consumed since their diagnosis ( n = 343) completed an anonymous, mixed-mode survey. Questions assessed usual mode delivery (MOD), THC/CBD concentration, how source acquisition, current use, instruction are concentration. Chi-square separate binary logistic regression analyses were examined weighted reflect the Roswell Park patient population. Results Less than 20% had products they across all MOD (smoking- combustible products, vaping- vaporized (e-cigarettes), edibles-eating drinking it, oral- taking by mouth (pills)). Source acquisition (smoking-AOR:4.6, p < 0.01, vaping-AOR:5.8, 0.00, edibles-AOR:2.6, 0.04), (edibles-AOR:5.4, vaping-AOR: 11.2, oral-AOR:9.3, 0.00), (vaping only AOR:4.2, 0.05) found be variables higher Conclusion Self-reported statistically differed according MOD, instruction,
Язык: Английский
Процитировано
1
Journal of Affective Disorders, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
1
Psychological Medicine, Год журнала: 2023, Номер 54(2), С. 245 - 255
Опубликована: Окт. 26, 2023
Abstract Cannabis use is consistently associated with both increased incidence of frank psychotic disorders and acute exacerbations symptoms in healthy individuals people psychosis spectrum disorders. Although there uncertainty around causality, cannabis may be one a few modifiable risk factors for conversion to Clinical High Risk Psychosis (CHR-P) syndromes, characterized by functionally impairing distressing subthreshold symptoms. To date, recommendations beyond abstinence reduce adverse psychiatric events have been made. This narrative review synthesizes existing scientific literature on cannabis' psychotomimetic effects epidemiological associations CHR-P bridge the gap between knowledge practical mental health intervention. There compelling evidence acutely exacerbating CHR-P, but its impact disorder unclear. Current supports harm reduction approach reducing frequency psychotic-like experiences, though whether such interventions decrease individuals' remains unknown. Specific include use, lowering delta-9-tetrahydrocannabinol content favor cannabidiol-only products, avoiding products inconsistent potency like edibles, enhancing patient-provider communication about utilizing collaborative individualized therapeutic approach. Despite surrounding causal association disorders, cautious attempts benefit uninterested abstinence. Further research needed clarify practices minimization cannabis-related risk.
Язык: Английский
Процитировано
2
Pharmacy, Год журнала: 2024, Номер 12(4), С. 100 - 100
Опубликована: Июнь 27, 2024
Although preliminary evidence suggests Cannabis's efficacy in symptom control for anxiety and depression-psychiatric disorders that significantly impact mental health-much remains to be understood about its effects on the central nervous system (CNS) how optimize treatment these disorders. This study aims conduct a narrative review evaluate pharmaceutical care treating symptoms of depression alongside Cannabis use, focusing safety therapeutic optimization. We seek conceptualize disorders, quality, identify knowledge gaps. Twelve articles were identified, revealing significant gap literature regarding integration with Cannabis-based therapies, specifically depression. Despite growing interest relationship between health, current research is insufficient comprehensive understanding. The use requires further, more targeted investigations. underscores importance future fill existing gaps, providing informed insights robust guidelines safe effective as part It crucial integrates therapies responsibly improve overall well-being patients.
Язык: Английский
Процитировано
0
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Окт. 17, 2024
There is growing recognition of the potential cannabis to treat various medical conditions and symptoms, such as chronic pain, spasticity, epilepsy. However, one biggest challenges assurance a standardized product that contains consistent amount its main psychoactive substances delta-9-tetrahydrocannabinol (THC) cannabidiol (CBD), which compliant with predetermined specifications for these compounds. This crucial not only ensure quality dosage patients but also effectively translate research findings into clinical practice.
Язык: Английский
Процитировано
0